entertainment -WSS

entertainment

author：comprehensive 2025-10-01 02:13:55 - browse：15

A sign of pharmaceutical company Bayer in front of a blossomed tree — coverage from STAT — INA FASSBENDER/AFP via Getty Images

More hopeful news on the menopause front: Bayer announced on Monday encouraging results in two Phase 3 trials for its non-hormonal drug candidate, elinzanetant, meant to treat hot flashes. The results follow the recent market launch of Veozah, Astellas Pharma’s groundbreaking non-hormonal treatment for hot flashes, which was approved by the U.S. Food and Drug Administration last spring and received approval in the U.K., under the name Veozah, in December.

Elinzanetant is a neurokinin-1 and 3 receptor antagonist, and works by calming down the estrogen receptors in the brain that become hyperactive around menopause, causing hot flashes. The drug, a pill administered once a day, was shown to reduce both the frequency and intensity of hot flashes, and also met the secondary endpoints for improving sleep and quality of life, according to JoAnn Pinkerton, professor of obstetrics and gynecology and director of the Midlife Health at UVA Health, who is a clinical investigator for Bayer’s drug candidate.

Pinkerton said she was excited to see the broader quality of life improvements through elinzanetant: “Women have more than just hot flashes — it’s actually more about hot flushes, sweats, fatigue, lack of sleep and some of the mood changes that go on during [menopause].”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： Clinical trials must include more disabled people

explore

leisure time

WSS

New details revealed about Purdue's marketing of OxyContin

ActiGraph execs on goal of drug approvals with digital endpoints

A neonatal nurse in a British hospital has been found guilty of killing 7 babies

Vaccine critic Robert F. Kennedy Jr. says he'll chair Trump vaccine panel

After half a century, Israel moves to evict squatter from his cave home on the beach

Digital health funding stays low as a new reality sets in

focus

entertainment

explore

In Memoriam: Notable people who died in 2023

New details revealed about Purdue's marketing of OxyContin

How one medical school became remarkably diverse

A Greenpeace activist is fined for crash

Jerome Adams on the need for new antivirals for Covid

Eye stem cell transplant could help restore vision in injured people

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Living with Hashimoto's and celiac disease, and med school, too

State Dept. review finds Biden bears some blame for Afghanistan failures

Sickle cell gene therapy cures need to be accessible in Africa

explore

EU fines Illumina $475 million over Grail acquisition

Vaccine critic Robert F. Kennedy Jr. says he'll chair Trump vaccine panel

Eye stem cell transplant could help restore vision in injured people

A Greenpeace activist is fined for crash

Kerry to visit Beijing for climate talks amid efforts to revive relations between US and China

ProMED sees offers of support, but its future remains unclear

leisure time

explore

leisure time

Wikipedia